| scholarly article | Q13442814 |
| P50 | author | Jude Fitzgibbon | Q60376856 |
| P2093 | author name string | Jessica Okosun | |
| Shamzah Araf | |||
| James Heward | |||
| Lola Koniali | |||
| P2860 | cites work | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Q24563021 |
| Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome | Q24622470 | ||
| Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma | Q24630610 | ||
| Regulation of chromatin by histone modifications | Q24635070 | ||
| The epigenetic basis of diffuse large B-cell lymphoma | Q26852288 | ||
| Hijacked in cancer: the KMT2 (MLL) family of methyltransferases | Q27006839 | ||
| Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin | Q27851546 | ||
| Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry | Q27853195 | ||
| A bivalent chromatin structure marks key developmental genes in embryonic stem cells | Q27860977 | ||
| Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers | Q28257103 | ||
| Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300 | Q28270979 | ||
| EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas | Q28741454 | ||
| Inactivating mutations of acetyltransferase genes in B-cell lymphoma | Q29031276 | ||
| Epigenetics in cancer | Q29547853 | ||
| Highly recurrent TERT promoter mutations in human melanoma | Q29614798 | ||
| TERT promoter mutations in familial and sporadic melanoma | Q29614920 | ||
| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations | Q29615392 | ||
| Cis-regulatory somatic mutations and gene-expression alteration in B-cell lymphomas. | Q30374056 | ||
| Concise review: epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells | Q30441798 | ||
| Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia | Q33401766 | ||
| Genetics of follicular lymphoma transformation | Q33910446 | ||
| Analysis of the coding genome of diffuse large B-cell lymphoma | Q34205133 | ||
| A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells | Q34302726 | ||
| KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation | Q34385576 | ||
| H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation | Q34394362 | ||
| Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas | Q34397318 | ||
| Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma | Q34458974 | ||
| EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors | Q34460151 | ||
| Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity | Q34550775 | ||
| Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression | Q35145329 | ||
| Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation | Q35189915 | ||
| Pathogenesis of follicular lymphoma | Q36290288 | ||
| Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. | Q36835530 | ||
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation | Q36926825 | ||
| Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma | Q37164915 | ||
| EZH2 mutations are frequent and represent an early event in follicular lymphoma | Q37272035 | ||
| Array-based DNA methylation profiling in follicular lymphoma | Q37388672 | ||
| Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma | Q37533656 | ||
| Interplay between the cancer genome and epigenome | Q38094260 | ||
| Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer | Q38150711 | ||
| Common progenitor cells in mature B-cell malignancies: implications for therapy | Q38210394 | ||
| Investigational epigenetically targeted drugs in early phase trials for the treatment of haematological malignancies. | Q38214120 | ||
| Germinal centres and B cell lymphomagenesis | Q38364884 | ||
| Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation | Q39614645 | ||
| EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis | Q41543905 | ||
| Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma | Q41645565 | ||
| Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. | Q41872521 | ||
| Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma | Q42696493 | ||
| Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction | Q47299700 | ||
| Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals | Q48074034 | ||
| The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining | Q48375088 | ||
| Mice homozygous for a truncated form of CREB-binding protein exhibit defects in hematopoiesis and vasculo-angiogenesis. | Q52177678 | ||
| Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. | Q54310538 | ||
| EZH2 Y641 mutations in follicular lymphoma. | Q54392744 | ||
| A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis | Q57261238 | ||
| Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) | Q59085244 | ||
| Genomic and epigenomic co-evolution in follicular lymphomas | Q60345277 | ||
| Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas | Q69406382 | ||
| Long-term clonal persistence and evolution of t(14;18)-bearing B cells in healthy individuals | Q81528379 | ||
| Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome | Q87141798 | ||
| Quantification of DAPK1 promoter methylation in bone marrow and peripheral blood as a follicular lymphoma biomarker | Q87847008 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 77-84 | |
| P577 | publication date | 2015-12-23 | |
| P1433 | published in | Epigenomics | Q20737165 |
| P1476 | title | Epigenetic dysregulation in follicular lymphoma | |
| P478 | volume | 8 |
| Q55263249 | A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. |
| Q48185856 | Current prognostic and predictive factors in follicular lymphoma |
| Q49489514 | IW-Scoring: an Integrative Weighted Scoring framework for annotating and prioritizing genetic variations in the noncoding genome |
| Q38647938 | Integrative whole-genome sequence analysis reveals roles of regulatory mutations in BCL6 and BCL2 in follicular lymphoma |
| Q38787141 | New targeted therapies for malignant lymphoma based on molecular heterogeneity |
Search more.